Tin tức & Cập nhật

Nanvuranlat confers PFS gains in advanced, refractory biliary tract cancer

The investigational L-type amino acid transporter 1 inhibitor nanvuranlat has an acceptable safety profile and is associated with prolonged progression-free survival (PFS) in patients with advanced and refractory biliary tract cancer when used in later-line treatment settings, according to the results of a phase II study.

Ultraprocessed food intake ups death risk in people with cancer history

Regular consumption of ultraprocessed food (UPF) among individuals with a history of cancer appears to increase the risk of mortality, suggests a study.

Medical cannabinoids come with risks for paediatric use

Cannabinoids for medical purposes in children and adolescents have been linked to increased risk of adverse events (AEs), according to the results of a meta-analysis.

5-fraction preoperative RT exhibits top-notch local control for soft tissue sarcoma

Patients with soft tissue sarcoma (STS) who underwent preoperative 5-fraction radiation therapy (RT) exhibit excellent 2-year local control with major wound complications (MWC) and experience toxicity akin to standard fractionation preoperative RT, a study has shown.

Virtual palliative care confers quality of life improvements in advanced NSCLC

Telehealth delivery of early palliative care positively affects quality of life in patients with advanced non–small cell lung cancer (NSCLC) the same way an in-person delivery does, according to a study.

Ponsegromab increases weight in patients with cancer cachexia

Use of ponsegromab is associated with increased weight gain and reduced cachexia symptoms in patients with cancer cachexia, according to results of a phase II, randomized, double-blind study.

Cập nhật kết quả nghiên cứu RIGHT Choice

Nghiên cứu RIGHT Choice của GS. Lu Y-S, Mahidin B, Azim H và cộng sự vừa được đăng tải trên tạp chí Ung thư học Lâm sàng (Journal of Clinical Oncology) của Hoa Kỳ tháng 5 năm 2024.

Tại thời điểm hiện tại, RIGHT Choice là nghiên cứu so sánh đối đầu đầu tiên về hiệu quả và tính an toàn giữa một thuốc ức chế CDK4/6 (ribociclib) so với phác đồ hóa trị kết hợp trên bệnh nhân ung thư vú HR+ HER2- có tình trạng bệnh di căn nặng trên lâm sàng như di căn tạng/ngoài tạng có triệu chứng, bệnh tiến triển nhanh hoặc có khủng hoảng tạng đe dọa tính mạng.

HK pioneers histotripsy in Asia for liver tumours

Hong Kong has become the first in Asia to introduce histotripsy – a nonthermal, nonionizing, noninvasive, focused ultrasound technique that induces cavitation and mechanical destruction of tissue at a focal point – for treatment of liver tumours in clinical trials.